Literature DB >> 2413370

The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.

B Hazelhoff, J B De Vries, D Dijkstra, W de Jong, A S Horn.   

Abstract

N-methyl-N-propargyl-2-aminotetralin (N-0425), a semi rigid analogue of deprenyl was found to be a potent inhibitor of monoamine oxidase type-A and -B. The MAO inhibitory potency was determined in in-vitro, ex-vivo and in-vivo experiments for racemic N-0425 and for both enantiomers, and compared with deprenyl. Racemic N-0425 and (-)N-0425 were found to inactivate both MAO-A and -B to about the same extent in rat brain homogenates, whereas (+)N-0425 was 10 times more potent in inhibiting MAO-B than MAO-A under in-vitro conditions. The latter compound was almost 3 times less active than (-)deprenyl with respect to inactivation of MAO-B. In ex-vivo experiments it was shown that (+/-)- and (+)N-0425 inhibited rat striatal MAO-B activity almost completely 2 h after a dose of 0.01 mmol/kg ip, whereas both compounds produced a much less rapid inactivation of type-A MAO, which was about 65% after 23 h. No potentiation of the tyramine induced increase in systolic blood pressure was found in normotensive rats following doses up to 0.01 mmol/kg ip of racemic N-0425, but a potentiation was observed after a higher dose of 0.04 mmol/kg. Levels of dopamine and noradrenaline were both increased in rat frontal cortex after the administration of N-0425, which can be interpreted as a reflection of MAO inactivation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413370     DOI: 10.1007/bf00586709

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  32 in total

1.  A SENSITIVE AND SPECIFIC ASSAY FOR THE ESTIMATION OF MONOAMINE OXIDASE.

Authors:  R J WURTMAN; J AXELROD
Journal:  Biochem Pharmacol       Date:  1963-12       Impact factor: 5.858

2.  Neonatal chemical sympathectomy: functional control of denervation of the vascular system and tissue noradrenaline level in the rat after 6-hydroxydopamine.

Authors:  A P Provoost; B Bohus; W de Jong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

3.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

4.  (-)Deprenyl in the treatment of Parkinson's disease.

Authors:  W Birkmayer; P Riederer; M B Youdim
Journal:  Clin Neuropharmacol       Date:  1982       Impact factor: 1.592

5.  Recent observations on the clinical pharmacology of (-)deprenyl.

Authors:  G M Stern; A J Lees; M Sandler
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

6.  Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl.

Authors:  V Glover; C J Pycock; M Sandler
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

7.  Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat.

Authors:  R M Cohen; I C Campbell; I Yamaguchi; D Pickar; I J Kopin; D L Murphy
Journal:  Eur J Pharmacol       Date:  1982-05-07       Impact factor: 4.432

8.  Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity.

Authors:  D Pickar; R M Cohen; D C Jimerson; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone.

Authors:  C J Fowler; M S Benedetti
Journal:  J Neurochem       Date:  1983-06       Impact factor: 5.372

10.  Dopamine oxidation and its inhibition by (-)-deprenyl in man.

Authors:  V Glover; J D Elsworth; M Sandler
Journal:  J Neural Transm Suppl       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.